Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion, Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, Zanubrutinib, Mosunetuzumab, Columvi 10 mg concentrate for solution for infusion, Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, BGB-16673, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11
BGB-16673-104
Phase 2 small_molecule active
Quick answer
Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion, Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, Zanubrutinib, Mosunetuzumab, Columvi 10 mg concentrate for solution for infusion, Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, BGB-16673, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11 for Relapsed or Refractory B-Cell Malignancies is a Phase 2 program (small_molecule) at Beone Medicines Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Beone Medicines Ireland Limited
- Indication
- Relapsed or Refractory B-Cell Malignancies
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active